Moreover, Mcl-1 is the target protein of the TRAIL signaling pathway, and the activation of TRAIL can downregulate the expression of Mcl-1 at the transcriptional and post-transcriptional levels, further indicating that Mcl-1 can be used as a target of cancer drugs [27]. This evidence concerns the gene TNFSF10 and cancer.